Investigating how LRRK2 mutations lead to nerve cell damage in Parkinson's disease
LRRK2 Enzymatic Mechanisms of Neurodegeneration in Parkinson's Disease
This study is looking at how changes in a specific gene called LRRK2 can harm nerve cells in people with Parkinson's disease, and it hopes to find new ways to help treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Van Andel Research Institute NIH-funded |
| Lab location | 1 site (Grand Rapids, United States) |
| Project ID | NIH-10986098 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms by which mutations in the LRRK2 gene contribute to the degeneration of nerve cells in Parkinson's disease. By studying the enzymatic functions of LRRK2, particularly its GTPase and kinase activities, the research aims to identify how these mutations lead to neuronal damage. The approach includes using cultured cells and animal models to observe the effects of these mutations on nerve cell health. The ultimate goal is to uncover potential therapeutic targets for treating Parkinson's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Parkinson's disease, particularly those with known LRRK2 mutations.
Not a fit: Patients with Parkinson's disease who do not have LRRK2 mutations may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent the progression of Parkinson's disease.
How similar studies have performed: Previous research has shown promise in targeting LRRK2 for therapeutic interventions, indicating a potential for success in this area.
Where this research is happening
Grand Rapids, United States
- Van Andel Research Institute — Grand Rapids, United States (Active)
Researchers
- Principal investigator: Moore, Darren John — Van Andel Research Institute
- Study coordinator: Moore, Darren John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.